Article

Low Serum 25-Hydroxyvitamin D Is Associated with Increased Risk of the Development of the Metabolic Syndrome at Five Years: Results from a National, Population-Based Prospective Study (The Australian Diabetes, Obesity and Lifestyle Study: AusDiab)

Centre hospitalier Universitaire de Québec, Centre hospitalier de l'Université Laval, Laval University, 2705 Boulevard Laurier, Québec, Canada G1V 4G2.
The Journal of Clinical Endocrinology and Metabolism (Impact Factor: 6.21). 03/2012; 97(6):1953-61. DOI: 10.1210/jc.2011-3187
Source: PubMed

ABSTRACT

Serum 25-hydroxyvitamin D [25(OH)D] concentration has been inversely associated with the prevalence of metabolic syndrome (MetS), but the relationship between 25(OH)D and incident MetS remains unclear.
We evaluated the prospective association between 25(OH)D, MetS, and its components in a large population-based cohort of adults aged 25 yr or older.
We used baseline (1999-2000) and 5-yr follow-up data of the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab).
Of the 11,247 adults evaluated at baseline, 6,537 returned for follow-up. We studied those without MetS at baseline and with complete data (n = 4164; mean age 50 yr; 58% women; 92% Europids).
We report the associations between baseline 25(OH)D and 5-yr MetS incidence and its components, adjusted for age, sex, ethnicity, season, latitude, smoking, family history of type 2 diabetes, physical activity, education, kidney function, waist circumference (WC), and baseline MetS components.
A total of 528 incident cases (12.7%) of MetS developed over 5 yr. Compared with those in the highest quintile of 25(OH)D (≥34 ng/ml), MetS risk was significantly higher in people with 25(OH)D in the first (<18 ng/ml) and second (18-23 ng/ml) quintiles; odds ratio (95% confidence interval) = 1.41 (1.02-1.95) and 1.74 (1.28-2.37), respectively. Serum 25(OH)D was inversely associated with 5-yr WC (P < 0.001), triglycerides (P < 0.01), fasting glucose (P < 0.01), and homeostasis model assessment for insulin resistance (P < 0.001) but not with 2-h plasma glucose (P = 0.29), high-density lipoprotein cholesterol (P = 0.70), or blood pressure (P = 0.46).
In Australian adults, lower 25(OH)D concentrations were associated with increased MetS risk and higher WC, serum triglyceride, fasting glucose, and insulin resistance at 5 yr. Vitamin D supplementation studies are required to establish whether the link between vitamin D deficiency and MetS is causal.

Download full-text

Full-text

Available from: Ken Andrew Sikaris, Jul 16, 2015
  • Source
    • "Serum concentrations of 25(OH)-Vit D < 50 nmol/L (20 ng/mL) is accepted as a marker of deficiency, whereas a concentration of 51-74 nmol/L (21-29 ng/mL) indicates insufficiency [91] [93] [96]. VitD deficiency has been shown to associate with increased susceptibility to both infections and cancer [24] [25] [96] [97] [98] [99] [100] [101]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic hepatitis C (CHC) is one of the most common causes of liver diseases worldwide, affecting 3% of the world population and 3 to 4 million people acquire new infection annually. Despite the recent introduction of novel antiviral drugs for the treatment of CHC, these drugs are expensive and the access to them is not an option for many patients. Hence, the traditional therapy by pegylated interferon-α (Peg-IFN-α) and ribavirin may still have a role in the clinical management of CHC especially in developing countries. However, this standard therapy is associated with several severe extra-hepatic side effects and the most common adverse events are hematological abnormalities and thyroid disorders and they could result in dose reduction and/or termination of therapy. Vitamin D has been shown to be a key regulatory element of the immune system, and its serum concentrations correlate with the severity of liver damage and the development of liver fibrosis/cirrhosis. Furthermore, supplementation with vitamin D with Peg-IFN-α based therapy for the treatment of CHC could be beneficial in increase the response rate to Peg-INF-α based therapy. Vitamin D has also been shown to regulate the thyroid functions and the process of erythropoiesis. This review appraises the data to date researching the role of vitamin D during the treatment of CHC and the potential role of vitamin D in preventing/treating Peg-IFN-α induced thyroiditis and anemia during the course of treatment.
    Full-text · Article · Sep 2015 · International Journal of Clinical and Experimental Medicine
  • Source
    • "Those with type 2 diabetes have lower serum 25–hydroxyvi- tamin D [25(OH)D] concentrations than their healthy counterparts [2] [3] [4]. Prospective studies [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] and randomized controlled trials [17] [18] [19] [20] have found a vitamin D association with type 2 diabetes and its metabolic indicators. A recent meta-analysis including both longitudinal cohort studies and randomized controlled trials of vitamin D supplementation found that higher baseline 25 (OH)D levels in prospective studies predicted a lower diabetes risk [21]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Higher serum 25-hydroxyvitamin D [25(OH)D] concentrations have been associated with lower risk of type 2 diabetes. This study compared incidence rates of type 2 diabetes among participants aged ≥20 years in two U.S. cohorts with markedly different median 25(OH)D concentrations. The median 25(OH)D concentration in the Grassroots Health (GRH) cohort was 41ng/ml (N=4933) while in the 2005-6 National Health and Nutrition Examination Survey (NHANES) it was 22ng/ml (N=4078) (P<0.0001). The adjusted annual incidence rate of type 2 diabetes was 3.7 per 1000 population (95% confidence interval=1.9, 6.6) in the GRH cohort, compared to 9.3 per 1000 population (95% confidence interval=6.7, 12.6) in NHANES. In the NHANES cohort, the lowest 25(OH)D tertiles (<17, 17-24ng/ml) had higher odds of developing diabetes than the highest tertile (OR: 4.9, P=0.02 and 4.8, P=0.01 respectively), adjusting for covariates. Differences in demographics and methods may have limited comparability. Raising serum 25(OH)D may be a useful tool for reducing risk of diabetes in the population. Copyright © 2015. Published by Elsevier Ltd.
    Full-text · Article · Jul 2015 · The Journal of steroid biochemistry and molecular biology
  • Source
    • "Serum concentrations of 25(OH)-Vit D < 50 nmol/L (20 ng/mL) is accepted as a marker of deficiency, whereas a concentration of 51-74 nmol/L (21-29 ng/mL) indicates insufficiency [91, 93, 96]. VitD deficiency has been shown to associate with increased susceptibility to both infections and cancer [24, 25,96979899100101. Recent findings in HCV mono-infected patients have also shown a correlation between low serum levels of 25-OH vitamin D3 and severe liver fibrosis102103104. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic hepatitis C (CHC) is one of the most common causes of liver diseases worldwide, affecting 3% of the world population and 3 to 4 million people acquire new infection annually. Despite the recent introduction of novel antiviral drugs for the treatment of CHC, these drugs are expensive and the access to them is not an option for many patients. Hence, the traditional therapy by pegylated interferon-alpha (Peg-IFN-alpha) and ribavirin may still have a role in the clinical management of CHC especially in developing countries. However, this standard therapy is associated with several severe extra-hepatic side effects and the most common adverse events are hematological abnormalities and thyroid disorders and they could result in dose reduction and/or termination of therapy. Vitamin D has been shown to be a key regulatory element of the immune system, and its serum concentrations correlate with the severity of liver damage and the development of liver fibrosis/cirrhosis. Furthermore, supplementation with vitamin D with Peg-IFN-alpha based therapy for the treatment of CHC could be beneficial in increase the response rate to Peg-INF-alpha based therapy. Vitamin D has also been shown to regulate the thyroid functions and the process of erythropoiesis. This review appraises the data to date researching the role of vitamin D during the treatment of CHC and the potential role of vitamin D in preventing/treating Peg-IFN-alpha induced thyroiditis and anemia during the course of treatment.
    Full-text · Article · Jan 2015 · International Journal of Clinical and Experimental Medicine
Show more